| Discordant impact of HLA on viral replicative capacity and disease progression in pediatric and adult HIV infection E Adland, P Paioni, C Thobakgale, L Laker, L Mori, M Muenchhoff, ... PLoS pathogens 11 (6), e1004954, 2015 | 62 | 2015 |
| Long-range transcriptional control of an operon necessary for virulence-critical ESX-1 secretion in Mycobacterium tuberculosis DM Hunt, NP Sweeney, L Mori, RH Whalan, I Comas, L Norman, T Cortes, ... Journal of bacteriology 194 (9), 2307-2320, 2012 | 53 | 2012 |
| The block-and-lock strategy for human immunodeficiency virus cure: lessons learned from didehydro–cortistatin A C Li, L Mori, ST Valente The Journal of Infectious Diseases 223 (Supplement_1), S46-S53, 2021 | 36 | 2021 |
| Sex differences in antiretroviral therapy initiation in pediatric HIV infection M Mori, E Adland, P Paioni, A Swordy, L Mori, L Laker, M Muenchhoff, ... PloS one 10 (7), e0131591, 2015 | 36 | 2015 |
| Key players in HIV-1 transcriptional regulation: targets for a functional cure L Mori, ST Valente Viruses 12 (5), 529, 2020 | 32 | 2020 |
| Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infection E Adland, J Millar, N Bengu, M Muenchhoff, R Fillis, K Sprenger, ... Nature Communications 11 (1), 1767, 2020 | 21 | 2020 |
| Modeling HIV-1 Latency Using Primary CD4+ T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy H Takata, C Kessing, A Sy, N Lima, J Sciumbata, L Mori, RB Jones, ... Journal of virology 93 (11), 10.1128/jvi. 02248-18, 2019 | 14 | 2019 |
| Recovery of effective HIV-specific CD4+ T-cell activity following antiretroviral therapy in paediatric infection requires sustained suppression of viraemia E Adland, L Mori, L Laker, A Csala, M Muenchhoff, A Swordy, M Mori, ... Aids 32 (11), 1413-1422, 2018 | 14 | 2018 |
| The XPB subunit of the TFIIH complex plays a critical role in HIV-1 transcription, and XPB inhibition by spironolactone prevents HIV-1 reactivation from latency L Mori, K Jenike, YHJ Yeh, B Lacombe, C Li, AJ Getzler, S Mediouni, ... Journal of Virology 95 (4), 10.1128/jvi. 01247-20, 2021 | 11 | 2021 |
| Cure and long-term remission strategies L Mori, ST Valente HIV Reservoirs: Methods and Protocols, 391-428, 2022 | 8 | 2022 |
| Mechanisms of non-pathogenicity in HIV: Lessons from paediatric infection E Adland, L Laker, L Mori, J Hurst, P Jooste, P Goulder 20th International AIDS conference. International AIDS Society, Melbourne …, 2014 | 6 | 2014 |
| HIV-1 transcriptional modulation: Novel host factors and prospective therapeutic strategies QMR Gibaut, LP Mori, ST Valente Current Opinion in HIV and AIDS 18 (5), 264-272, 2023 | 5 | 2023 |
| The chaperone protein p32 stabilizes HIV-1 Tat and strengthens the p-TEFb/RNAPII/TAR complex promoting HIV transcription elongation C Li, LP Mori, S Lyu, R Bronson, AJ Getzler, ME Pipkin, ST Valente Proceedings of the National Academy of Sciences 120 (1), e2217476120, 2023 | 5 | 2023 |
| OP 1.5–00046 P400/Tip60 chromatin remodeling complex in HIV transcription and latency establishment L Mori, C Li, T Venables, R Bronson, ME Pipkin, ST Valente Elsevier, 2022 | 1 | 2022 |
| The host factor p32 facilitates HIV infection by stabilizing the HIV-1 transcriptionaltrans-activatorTat protein L Mori, C Li, S Lyu, A Getzler, M Pipkin, S Valente JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 25, 66-66, 2022 | | 2022 |
| PP 1.29–00158 The chaperone protein p32 stabilizes HIV-1 Tat and strengthens the p-TEFb/RNAPII/TAR complex promoting HIV transcription elongation C Li, L Mori, S Lyu, R Bronson, A Getzler, M Pipkin, ST Valente | | 2022 |
| Author Correction: Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infection E Adland, J Millar, N Bengu, M Muenchhoff, R Fillis, K Sprenger, ... Nature communications 11 (1), 1-1, 2020 | | 2020 |
| Degradation of the XPB subunit of TFIIH by spironolactone reduces HIV-1 reactivation from latency L Mori, YC Ho, BC Ramirez, S Valente | | 2019 |
| Viral Evasion of Immune Control Mediated by Coexpression of HLA-B* 27: 05 and HLA-B* 57: 01 J Brener, F Chen, L Riddell, F Pereyra, L Mori, E Adland, N Robinson, ... | | 2013 |
